2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 196

Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 793

Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 740

Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 371

Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 39

Role of Sialic Acid in the Aggressive Phenotype of RA FLS

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 24

Role of Trained Immunity in the Pathogenesis of Erdheim-Chester Disease

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 10

Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 489

S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 527

Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 712

Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 509

Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 569

Sarcopenia, Segmental Muscle Strength and Body Composition in Young Axial Spondylarthritis Patients: Results from MyoSpA Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 313

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 399

Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 380

Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].